Balaxi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
- Paid Up Capital ₹ 11.04 Cr
- Company Age 82 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 35.00 Cr
- Satisfied Charges ₹ 34.29 Cr
- Revenue Growth 17.32%
- Profit Growth -3.08%
- Ebitda -8.61%
- Net Worth 33.92%
- Total Assets 18.86%
About Balaxi Pharmaceuticals
Balaxi Pharmaceuticals Limited (BPL) was founded in India on 28 September 1942 and has a glorious history of 82 years and four months. Its registered office is in Hyderabad, Telangana, India.
It is listed on the National Stock Exchange(NSE) under the ticker symbol BALAXI.
The Corporate was formerly known as The Anandam Rubber Company Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 11.04 Cr.
The company currently has active open charges totaling ₹35.00 Cr. The company has closed loans amounting to ₹34.29 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Balaxi Pharmaceuticals Limited India are Amol Mantri as CFO and Mohith Khandelwal as Company Secretary. Kunal Bhakta, Gandhi Gamji, Akshita Surana, and Three other members serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
L25191TG1942PLC121598
- Company No.
121598
- Stock Symbol
NSE : BALAXI
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Sep 1942
- Date of AGM
23 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Balaxi Pharmaceuticals?
Executive Team (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Amol Mantri | CFO | 20-May-2021 | Current |
Mohith Khandelwal | Company Secretary | 21-Nov-2024 | Current |
Ashish Maheshwari ![]() | Managing Director | 04-May-2017 | Current |
Board Members (5)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Kunal Bhakta ![]() | Director | 04-May-2017 | Current |
Gandhi Gamji ![]() | Director | 04-May-2017 | Current |
Akshita Surana ![]() | Director | 05-Sep-2024 | Current |
Mangina Srinivas ![]() | Director | 15-Sep-2020 | Current |
Maheshwari Minoshi ![]() | Director | 04-May-2017 | Current |
Financial Performance of Balaxi Pharmaceuticals.
Balaxi Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17.32% increase. The company also saw a slight decrease in profitability, with a 3.08% decrease in profit. The company's net worth Soared by an impressive increase of 33.92%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Balaxi Pharmaceuticals?
In 2023, Balaxi Pharmaceuticals had a promoter holding of 71.56% and a public holding of 28.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹35.00 Cr
₹34.29 Cr
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 35.00 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
16 Sep 2024 | Yes Bank Limited | ₹35.00 Cr | Open |
26 Jul 2022 | Others | ₹31.00 Cr | Satisfied |
29 Jun 2021 | Yes Bank Limited | ₹1.00 Cr | Satisfied |
23 Jun 2020 | Others | ₹2.10 M | Satisfied |
22 Apr 2015 | Hedge Finance Limited | ₹2.00 Cr | Satisfied |
How Many Employees Work at Balaxi Pharmaceuticals?
Balaxi Pharmaceuticals has a workforce of 49 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Balaxi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Balaxi Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.